Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study

L. Canobbio, F. Boccardo, D. Cannata, P. Gallotti, R. Epis

Research output: Contribution to journalArticle

Abstract

Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.

Original languageEnglish
Pages (from-to)648-650
Number of pages3
JournalCancer
Volume69
Issue number3
Publication statusPublished - 1992

Fingerprint

Somatostatin
Pancreatic Neoplasms
Therapeutics
Exocrine Pancreas
Growth Hormone
lanreotide
Pancreatic Carcinoma
Appointments and Schedules
Pain
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. / Canobbio, L.; Boccardo, F.; Cannata, D.; Gallotti, P.; Epis, R.

In: Cancer, Vol. 69, No. 3, 1992, p. 648-650.

Research output: Contribution to journalArticle

Canobbio, L. ; Boccardo, F. ; Cannata, D. ; Gallotti, P. ; Epis, R. / Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. In: Cancer. 1992 ; Vol. 69, No. 3. pp. 648-650.
@article{856cac6d3a4a4532a31fa7063f439165,
title = "Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study",
abstract = "Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.",
author = "L. Canobbio and F. Boccardo and D. Cannata and P. Gallotti and R. Epis",
year = "1992",
language = "English",
volume = "69",
pages = "648--650",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study

AU - Canobbio, L.

AU - Boccardo, F.

AU - Cannata, D.

AU - Gallotti, P.

AU - Epis, R.

PY - 1992

Y1 - 1992

N2 - Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.

AB - Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.

UR - http://www.scopus.com/inward/record.url?scp=0026501635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026501635&partnerID=8YFLogxK

M3 - Article

C2 - 1346097

AN - SCOPUS:0026501635

VL - 69

SP - 648

EP - 650

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -